01.06.2018 15:00:00

Faruqi & Faruqi, LLP is Investigating Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of its Shareholders

NEW YORK, June 1, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities law violations at Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") (NASDAQ: SUPN).

Faruqi & Faruqi, LLP. (PRNewsfoto/Faruqi & Faruqi, LLP)

Request more information now by clicking here:  www.faruqilaw.com/SUPN. There is no cost or obligation to you.

Take Action

If you currently own Supernus stock and would like to discuss your legal rights, please visit www.faruqilaw.com/SUPN.  You can also contact us either by calling Nina M. Varindani toll free at (212) 983-9330 or by sending an e-mail to nvarindani@faruqilaw.com, or by sending an email to Michael Van Gorder at mvangorder@faruqilaw.com. Faruqi & Faruqi, LLP also encourages anyone with information regarding Supernus's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising.  The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).  Prior results do not guarantee or predict a similar outcome with respect to any future matter.  We welcome the opportunity to discuss your particular case.  All communications will be treated in a confidential manner.

CONTACT:
Nina M. Varindani
Michael Van Gorder
FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
nvarindani@faruqilaw.com 
mvangorder@faruqilaw.com  
Telephone: (212) 983-9330

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/faruqi--faruqi-llp-is-investigating-supernus-pharmaceuticals-inc-supn-on-behalf-of-its-shareholders-300657905.html

SOURCE Faruqi & Faruqi, LLP

Analysen zu Supernus Pharmaceuticals Incmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Supernus Pharmaceuticals Inc 34,60 -0,57% Supernus Pharmaceuticals Inc